News|Articles|October 31, 2025
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
Author(s)PharmExec Staff
Listen
0:00 / 0:00
Key Takeaways
- The MFN model, DTC channels, and tariffs are set to transform drug market dynamics, affecting key stakeholders like payers and manufacturers.
- The webinar will evaluate if MFN is a sustainable reform or merely a political issue, impacting future healthcare policies.
Join us for a premium webinar on November 4, 2025!
Advertisement
With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals would be fundamentally reshaped.
Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets
On November 4, this exclusive webinar will cut through the political noise and provide a critical, operational analysis of these seismic shifts. We will explore whether MFN is a foundation for permanent reform or simply a political flashpoint, how the proposed mandatory payment models GLOBE and GUARD fit into the future, and what the real-world impact of tariffs and DTC channels will be.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
The Evolving Relationship Between FDA and Biotech
5